Caplyta Bipolar Mania: Second Phase 3 Win Sets Up J&J FDA Filing
J&J’s Caplyta (lumateperone) beat placebo in Study 452, its second pivotal Phase 3 trial in bipolar I mania, clearing the way for an FDA filing. Here is how the two studies compare.
J&J’s Caplyta (lumateperone) beat placebo in Study 452, its second pivotal Phase 3 trial in bipolar I mania, clearing the way for an FDA filing. Here is how the two studies compare.
Envudeucitinib plaque psoriasis: Alumis reports 54% complete skin clearance at 48 weeks in Phase 3 ONWARD3 and plans an NDA in Q4 2026.
AJ201 (rosolutamide) moves into the pivotal Phase 3 ROMA-KD trial for Kennedy disease, or SBMA. Mechanism, earlier data and what is unknown.